Psoriasis Clinical Trial
Official title:
Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness
UVB phototherapy is a commonly used treatment for patients with psoriasis. Generally it is
performed in the outpatient department of the hospital. The UVB irradiation itself will
normally take only a few minutes, but to receive the irradiation patients have to travel to
the outpatient department during working hours 2 or 3 times a week. In general it is a
relatively time-consuming treatment.
Objective of this study is to assess whether UVB treatment administered in the home is as
equally effective as the standard outpatient UVB phototherapy. Quality of life and
cost-effectiveness are also studied.
Psoriasis is a chronic recurrent skin disorder characterised by erythematosquamous lesions
(plaques). Usually the abnormal areas are few, but occasionally the disease is more
generalised. Psoriasis can be treated locally by application of creams and ointments, for
instance corticosteroids and vitamin D3. For most patients topical therapy will suffice.
However, for some patients the area involved is such that topical application is not
feasible. Or for others, the skin lesions do not respond anymore to topical treatment. In
that case the dermatologist may start irradiation with ultraviolet (UV) light or prescribe
systemic medication.
UVB phototherapy is a commonly used treatment for patients with psoriasis. Generally it is
performed in the outpatient department of the hospital. The UVB irradiation itself will
normally take only a few minutes, but to receive the irradiation patients have to travel to
the outpatient department during working hours 2 or 3 times a week. In general it is a
relatively time-consuming treatment.
To overcome the drawbacks of UVB treatment in the outpatient clinic, home UVB phototherapy
was introduced over 25 years ago. However, the safety and effectiveness of home UVB have
been debated ever since. Despite all discussion, the number of dermatologists prescribing
home UVB phototherapy to their patients seems to gradually increase. We recently
demonstrated that there is no sound evidence that would either support or dissuade from
prescribing home UVB phototherapy. Particularly the lack of randomised research is apparent.
Therefore, the objective of this study is to assess whether UVB treatment administered in
the home is as equally effective as the standard outpatient UVB phototherapy. Quality of
life and cost-effectiveness are also studied.
Primary Outcome:
(SA)PASI at inclusion, start of therapy, 23 (20-26) irradiations, end of therapy, and at
every 2 months after end of therapy (maximum 1 year) Quality of life scores (EQ-5D, SF-36,
PDI) at inclusion, start of therapy, 23 (20-26) irradiations and at end of therapy.
Costs and Cost-Effectiveness will be calculated with a time-horizon of 12 months after
inclusion (questionnaires were used at inclusion, start of therapy, 23 (20-26) irradiations,
end of therapy, and at every 2 months after end of therapy (maximum 1 year))
Secondary Outcome:
Cumulative dosimetry (every irradiation) Total amounts of and types of side-effects (every
irradiation) Concomitant use of medication (during the whole trial, data derived from
patients' pharmacists)
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
| Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
| Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
| Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
| Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
| Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
| Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
| Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
| Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
| Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
| Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
| Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
| Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
| Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
| Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
| Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
| Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
| Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
| Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |